<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02229929</url>
  </required_header>
  <id_info>
    <org_study_id>CR845-CLIN2005</org_study_id>
    <nct_id>NCT02229929</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Intravenous CR845 in Hemodialysis Patients, and Its Safety and Efficacy in Hemodialysis Patients With Uremic Pruritus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cara Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cara Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to:&#xD;
&#xD;
        -  Evaluate the safety and pharmacokinetic profile of repeated doses IV CR845 over one week&#xD;
           in patients who are undergoing hemodialysis. (Part A)&#xD;
&#xD;
        -  This study is also investigating whether repeated doses of IV CR845 over two weeks is&#xD;
           safe and effective in reducing the intensity of itching in hemodialysis patients with&#xD;
           uremic pruritus (Part B).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Placebo-controlled&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Determine the Pharmacokinetics of Repeated Doses of CR845 in Hemodialysis Patients (half-life, Cmax, Tmax, AUC, Vd)</measure>
    <time_frame>1 week</time_frame>
    <description>To evaluate the pharmacokinetics of repeated doses of CR845 in hemodialysis patients over a one-week treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change in Worst Itching Intensity using a 100-mm Visual Analog Scale</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change from baseline to the average of Week 2 worst itching (daytime and nighttime) VAS where 0 mm represents &quot;No Itch&quot; and 100 mm represents the &quot;Worst Itch You Can Imagine&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part B: Change in quality-of-life assessed using the Skindex-10 survey</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change from baseline to Day 15 in itch-related quality of life as assessed by the total Skindex-10 scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Sleep disturbance assessed using Itch Medical Outcomes Study (MOS) survey</measure>
    <time_frame>2 weeks</time_frame>
    <description>Change from baseline to Day 15 in itch-related sleep disturbance based on the Itch MOS sleep problems index II (SLP-9)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Pruritus</condition>
  <condition>Uremic Pruritus</condition>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous matched placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: CR845 0.5 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous CR845, 0.5 mcg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: CR845 1.0 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous CR845, 1.0 mcg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: CR845 2.5 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous CR845, 2.5 mcg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous matched placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: CR845 1.0 mcg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous CR845, 1.0 mcg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part A: Placebo</intervention_name>
    <description>Part A: Single i.v. dose of Placebo administered after each dialysis session over a 1 week treatment period (3 times per week)</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <other_name>Matched Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part A: CR845 0.5 mcg/kg</intervention_name>
    <description>Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)</description>
    <arm_group_label>Part A: CR845 0.5 mcg/kg</arm_group_label>
    <other_name>CR845 0.5 mcg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part A: CR845 1.0 mcg/kg</intervention_name>
    <description>Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)</description>
    <arm_group_label>Part A: CR845 1.0 mcg/kg</arm_group_label>
    <other_name>CR845 1.0 mcg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part A: CR845 2.5 mcg/kg</intervention_name>
    <description>Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)</description>
    <arm_group_label>Part A: CR845 2.5 mcg/kg</arm_group_label>
    <other_name>CR845 2.5 mcg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part B: Placebo</intervention_name>
    <description>Part B: Single i.v. dose of Placebo administered after each dialysis session over a 2 week treatment period (3 times per week)</description>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <other_name>Matched Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part B: CR845 1.0 mcg/kg</intervention_name>
    <description>Part B: Single i.v. dose of CR845 administered after each dialysis session over a 2 week treatment period (3 times per week)</description>
    <arm_group_label>Part B: CR845 1.0 mcg/kg</arm_group_label>
    <other_name>CR845 1.0 mcg/kg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Able to provide written informed consent prior to any study procedures;&#xD;
&#xD;
          -  Able to communicate clearly with the Investigator and staff, able to read and&#xD;
             understand the study procedures;&#xD;
&#xD;
          -  Males or females 18 years of age or older;&#xD;
&#xD;
          -  End stage renal disease (ESRD) patients who have been on hemodialysis for at least&#xD;
             three months and are currently on hemodialysis:&#xD;
&#xD;
               -  At least three times per week (Part A)&#xD;
&#xD;
               -  Three times per week (Part B)&#xD;
&#xD;
          -  Has a body weight â‰¤ 135 kg&#xD;
&#xD;
          -  Part B: Patient who self-reports daily or near daily pruritus during the 6 weeks prior&#xD;
             to Screening;&#xD;
&#xD;
          -  Part B: Patient who reports a Patient B or Patient C profile on the Patient&#xD;
             Self-categorization of Pruritus Disease Severity questionnaire at Screening;&#xD;
&#xD;
          -  Part B: At the end of the Run-in Period:&#xD;
&#xD;
               -  Patient who completed ratings of worst itching intensity [visual analog scale&#xD;
                  (VAS)] at least 8 times out of 14 VAS assessments;&#xD;
&#xD;
               -  Patient who has a mean value of &gt;40 mm on the worst itching VAS over the one week&#xD;
                  Run-in Period.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Known to be non-compliant with dialysis treatment (i.e., has a history of missed&#xD;
             dialysis sessions due to non-compliance in the past 2 months);&#xD;
&#xD;
          -  Anticipated to receive a kidney transplant during the study;&#xD;
&#xD;
          -  Known history of allergic reaction to opiates such as hives (Note: side effects&#xD;
             related to the use of opioids such as constipation or nausea would not exclude the&#xD;
             patients from the study);&#xD;
&#xD;
          -  Known or suspected history of Diagnostic and Statistical Manual of Mental Disorders,&#xD;
             Fifth Edition (DSM-5)-diagnosed alcohol, narcotic, or other drug abuse or dependence&#xD;
             within 12 months prior to Screening;&#xD;
&#xD;
          -  Acute or unstable medical condition(s) such as congestive heart failure [New York&#xD;
             Heart Association (NYHA) class IV], which in the opinion of the Investigator would&#xD;
             pose undue risk to the patient or would impede complete collection of the data or its&#xD;
             evaluability;&#xD;
&#xD;
          -  Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) greater than&#xD;
             2.5X the reference upper limit of normal (ULN), or bilirubin greater than 4X the ULN&#xD;
             at Screening;&#xD;
&#xD;
          -  Received another investigational drug within 30 days prior to the start of the Run-in&#xD;
             Period or has planned to participate in another clinical trial while enrolled in this&#xD;
             study&#xD;
&#xD;
          -  Part B: Has pruritus probably or definitely attributed to a cause other than ESRD or&#xD;
             its complications (e.g., patients with concomitant pruritic dermatological disease or&#xD;
             cholestatic liver disease would be excluded). (Note: Patients whose pruritus is&#xD;
             attributed to ESRD complications such as hyperparathyroidism, hyperphosphatemia,&#xD;
             anemia, or the dialysis procedure or prescription may be enrolled);&#xD;
&#xD;
          -  Part B: Has localized itch restricted to the palms of the hands as determined from the&#xD;
             Brief Itch Inventory diagram, completed during the Screening Period;&#xD;
&#xD;
          -  Part B: Has pruritus only during the dialysis session (by patient report);&#xD;
&#xD;
          -  Part B: Has used gabapentin, calcineurin inhibitors, opioids; antipsychotics; systemic&#xD;
             or topical corticosteroids (other than otic or ophthalmic preparations); sedatives;&#xD;
             hypnotics; anti-anxiety agents selective serotonin reuptake inhibitors (SSRIs); or&#xD;
             tricyclic antidepressants for &lt; 4 weeks prior to the start of the Run-In Period or had&#xD;
             a dose change within the previous 30 days;&#xD;
&#xD;
          -  Part B: Is not willing to abstain from use of antihistamines (oral, IV, or topical)&#xD;
             for 3 weeks (from the start of the Run-In Period through the end of Week 2);&#xD;
&#xD;
          -  Part B: Not willing to abstain from making changes to topical non-drug treatments&#xD;
             (e.g., emollients, creams, oils) for pruritus for 3 weeks (from the start of the&#xD;
             Run-In Period through the end of Week 2);&#xD;
&#xD;
          -  Part B: Received ultraviolet B treatment within 30 days prior to the start of the&#xD;
             Run-in Period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederique Menzaghi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cara Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US Renal Care</name>
      <address>
        <city>Pine Bluff</city>
        <state>Arkansas</state>
        <zip>71603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Renal Care</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Renal Care</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Renal Medical Group</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrology Specialists Medical Group, Inc</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North American Research Institute</name>
      <address>
        <city>San Dimas</city>
        <state>California</state>
        <zip>91773</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pines Clinical Research, Inc.</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Dialysis Center at Northside</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western New England Renal &amp; Transplant Associates, PC</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Renal Care</name>
      <address>
        <city>Gallup</city>
        <state>New Mexico</state>
        <zip>87301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trude Weishaupt Memorial Dialysis Center</name>
      <address>
        <city>Fresh Meadows</city>
        <state>New York</state>
        <zip>11365</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brookview Hills Research Associates, LLC</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Renal Care</name>
      <address>
        <city>Aiken</city>
        <state>South Carolina</state>
        <zip>29803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Renal Research Institute</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Renal Care</name>
      <address>
        <city>Grand Prairie</city>
        <state>Texas</state>
        <zip>75050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Renal Care</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 27, 2014</study_first_submitted>
  <study_first_submitted_qc>August 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2014</study_first_posted>
  <disposition_first_submitted>August 8, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>August 8, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 10, 2016</disposition_first_posted>
  <last_update_submitted>August 8, 2016</last_update_submitted>
  <last_update_submitted_qc>August 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pruritus</keyword>
  <keyword>uremic pruritus</keyword>
  <keyword>kappa opioid</keyword>
  <keyword>CR845</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

